tetano
Editor, Senior Moderator
Can Commun Dis Rep
. 2022 Apr 6;48(4):131-139.
doi: 10.14745/ccdr.v48i04a03.
The need for linked genomic surveillance of SARS-CoV-2
Caroline Colijn[SUP] 1 [/SUP], David Jd Earn[SUP] 2 [/SUP], Jonathan Dushoff[SUP] 3 [/SUP], Nicholas H Ogden[SUP] 4 [/SUP], Michael Li[SUP] 5 [/SUP], Natalie Knox[SUP] 6 [/SUP], Gary Van Domselaar[SUP] 6 [/SUP], Kristyn Franklin[SUP] 7 [/SUP], Gordon Jolly[SUP] 8 [/SUP], Sarah P Otto[SUP] 9 [/SUP]
Affiliations
Abstract
Genomic surveillance during the coronavirus disease 2019 (COVID-19) pandemic has been key to the timely identification of virus variants with important public health consequences, such as variants that can transmit among and cause severe disease in both vaccinated or recovered individuals. The rapid emergence of the Omicron variant highlighted the speed with which the extent of a threat must be assessed. Rapid sequencing and public health institutions' openness to sharing sequence data internationally give an unprecedented opportunity to do this; however, assessing the epidemiological and clinical properties of any new variant remains challenging. Here we highlight a "band of four" key data sources that can help to detect viral variants that threaten COVID-19 management: 1) genetic (virus sequence) data; 2) epidemiological and geographic data; 3) clinical and demographic data; and 4) immunization data. We emphasize the benefits that can be achieved by linking data from these sources and by combining data from these sources with virus sequence data. The considerable challenges of making genomic data available and linked with virus and patient attributes must be balanced against major consequences of not doing so, especially if new variants of concern emerge and spread without timely detection and action.
. 2022 Apr 6;48(4):131-139.
doi: 10.14745/ccdr.v48i04a03.
The need for linked genomic surveillance of SARS-CoV-2
Caroline Colijn[SUP] 1 [/SUP], David Jd Earn[SUP] 2 [/SUP], Jonathan Dushoff[SUP] 3 [/SUP], Nicholas H Ogden[SUP] 4 [/SUP], Michael Li[SUP] 5 [/SUP], Natalie Knox[SUP] 6 [/SUP], Gary Van Domselaar[SUP] 6 [/SUP], Kristyn Franklin[SUP] 7 [/SUP], Gordon Jolly[SUP] 8 [/SUP], Sarah P Otto[SUP] 9 [/SUP]
Affiliations
- PMID: 35480703
- PMCID: PMC9017802
- DOI: 10.14745/ccdr.v48i04a03
Abstract
Genomic surveillance during the coronavirus disease 2019 (COVID-19) pandemic has been key to the timely identification of virus variants with important public health consequences, such as variants that can transmit among and cause severe disease in both vaccinated or recovered individuals. The rapid emergence of the Omicron variant highlighted the speed with which the extent of a threat must be assessed. Rapid sequencing and public health institutions' openness to sharing sequence data internationally give an unprecedented opportunity to do this; however, assessing the epidemiological and clinical properties of any new variant remains challenging. Here we highlight a "band of four" key data sources that can help to detect viral variants that threaten COVID-19 management: 1) genetic (virus sequence) data; 2) epidemiological and geographic data; 3) clinical and demographic data; and 4) immunization data. We emphasize the benefits that can be achieved by linking data from these sources and by combining data from these sources with virus sequence data. The considerable challenges of making genomic data available and linked with virus and patient attributes must be balanced against major consequences of not doing so, especially if new variants of concern emerge and spread without timely detection and action.